Kybella is priced by the number of vials used, with smaller areas requiring fewer vials than larger areas
A phase III, randomized, double-blind, parallel-group study showed that the combination of SGLT2 inhibitors and DPP-4 inhibitors resulted in the reductions of HbA1c (mean baseline 7.908.02% [62.864.1 mmol/mol]), FPG, serum uric acid, SBP, and hypoglycemic risk were superior to those with the individual components in patients with T2DM
4 weeks: 1 vial uses 2 mL total
Some patients report that the daily injection becomes routine and less anxiety-provoking over time, whilst others find the frequency burdensome
However, only Wegovy (semaglutide GLP-1) has been specifically FDA-approved for weight loss
Consistent documentation provides objective evidence of medication efficacy, helps identify patterns between lifestyle factors and outcomes, and enables early recognition of adverse effects requiring intervention